Smith & Nephew is launching its dissolvable nasal dressing NasaStent. The intranasal splint is made of carboxymethyl cellulose that converts to a hydrocolloidal gel as nasal fluid is absorbed--it then simply drains from the nasal cavity. This gradual dissolution is expected to be less jarring for patients than the typical removal of other structural dressings, which must be taken out in fragments by a physician.
Orthopedics player Smith & Nephew is rounding out its presence in emerging markets with the acquisition of the trauma and orthopedics business as well as a manufacturing company of the DeOst Group. The Russian company manufactures medical devices and has also served as Smith & Nephew's product distributor in the region since 2009.
Orthopedics company Smith & Nephew plans to close its York, U.K., facility by the end of 2016, resulting in the relocation of 80 jobs.
Orthopedics specialist Smith & Nephew is removing particular hip implant sizes and related components from the market after data from the U.K.'s National Institute for Health and Care Excellence found that smaller sizes of the Birmingham Hip Resurfacing System had revision rates that exceed its benchmarked expectations. It's also advising against any use of the system in women. But despite the data, it's not advising that patients with the now-contraindicated implant have proactive revisions.
Outside of surgery, physicians can do very little to treat severe rotator cuff tears. Israeli company OrthoSpace is aiming to offer a new treatment option. It's raised an $8 million venture round led by Healthpoint Capital that will finance a pivotal, U.S. trial for the company's biodegradable balloon system InSpace.
With the acquisition of two medical software programs from Andover, MA's S2 Interactive, Smith & Nephew is throwing more chips on the table when it comes to its disruptive, rep-less sales pilot program.
The FDA slapped Smith & Nephew with a warning letter for quality-control violations at its Andover, MA, facility related to problems with some of the company's mechanical morcellators for removal of intrauterine tissue. The company has placed a hold on shipments of its Truclear Ultra Reciprocating Morcellator 4.0 while it further investigates customer complaints.
Smith & Nephew was down 8% on the March 3 news that Stryker now has a massive $2.6 billion authorization available for share repurchases. That's a significant shift in strategy for Stryker, which has been highly acquisitive in the last few years and has long been rumored as a potential buyer for Smith & Nephew.
Smith & Nephew is working toward having two-thirds of its revenue coming from higher growth areas. Acquisitions are core to that goal--in fact, during the fourth quarter any organic growth was wiped out by the impact from currency exchange and the only revenue growth came from its surgical devices acquisitions, which grew by 12%.
An aggressive acquisition strategy in order to broaden its product usage in trauma units and hospitals continues to be the focus for Stryker.